Cargando…

Valsartan/Sacubitril in heart failure and hypotension: how, when and why

Detalles Bibliográficos
Autores principales:	Scardovi, Angela Beatrice, Boccanelli, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439907/ https://www.ncbi.nlm.nih.gov/pubmed/30948960 http://dx.doi.org/10.1093/eurheartj/suz024

Ejemplares similares

Sudden death in ischemic heart disease: looking for new predictors: polygenic risk
por: Boccanelli, Alessandro, et al.
Publicado: (2023)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
por: Bocchi, Edimar Alcides, et al.
Publicado: (2018)

Renal protective effect of sacubitril/valsartan in patients with heart failure
por: Hsieh, Hui-Ling, et al.
Publicado: (2021)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
por: Carballo, David, et al.
Publicado: (2020)

Low dose sacubitril/valsartan is effective and safe in hemodialysis patient with decompensated heart failure and hypotension: A case report
por: Feng, Yunlin, et al.
Publicado: (2022)

Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
por: Heyse, Alex, et al.
Publicado: (2019)

Renal protection in chronic heart failure: focus on sacubitril/valsartan
por: Pontremoli, Roberto, et al.
Publicado: (2021)

Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure
por: Bano, Shehar, et al.
Publicado: (2021)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
por: Brioschi, Maura, et al.
Publicado: (2023)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure
por: Fröhlich, Hanna, et al.
Publicado: (2022)

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
por: Yandrapalli, Srikanth, et al.
Publicado: (2017)

Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
por: Cuthbert, Joseph J, et al.
Publicado: (2020)

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date
por: Akbar, Sara, et al.
Publicado: (2020)

Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure
por: Rao, Birju R., et al.
Publicado: (2022)

Use and Out‐of‐Pocket Cost of Sacubitril‐Valsartan in Patients With Heart Failure
por: Shore, Supriya, et al.
Publicado: (2022)

Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
por: Abdin, Amr, et al.
Publicado: (2022)

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
por: Iovanovici, Diana-Carina, et al.
Publicado: (2022)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
por: Mohebi, Reza, et al.
Publicado: (2023)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
por: Liu, Rex C.
Publicado: (2018)

Effects of Sacubitril/Valsartan on Glycemic Control in Japanese Patients With Heart Failure and/or Hypertension
por: Sazawa, Kahomi, et al.
Publicado: (2022)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
por: Khan, Muhammad Nauman, et al.
Publicado: (2023)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021)

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
por: Vilela-Martin, José Fernando
Publicado: (2016)

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
por: Jhund, Pardeep S, et al.
Publicado: (2016)

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018)

Use of sacubitril/valsartan in acute decompensated heart failure: a case report
por: Bell, Taison D., et al.
Publicado: (2017)

The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan
por: Yandrapalli, Srikanth, et al.
Publicado: (2017)

ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction
por: Kang, Min-Kyung
Publicado: (2020)

Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
por: Gregorietti, Vanesa, et al.
Publicado: (2020)

Efficacy of Sacubitril/Valsartan in the Setting of Acute Heart Failure: A Systematic Review
por: Mohyeldin, Moiud, et al.
Publicado: (2021)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021)

Sacubitril/Valsartan for heart failure: A protocol for systematic review and meta-analysis
por: Dai, Wenqin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pgmd6fios2aktd15r14j3ah7ob